Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Financing Activities (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash from Financing Activities for 16 consecutive years, with -$112000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 5500.0% to -$112000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$54.6 million, a 11.14% decrease, with the full-year FY2024 number at -$102.6 million, down 1407.06% from a year prior.
  • Cash from Financing Activities was -$112000.0 for Q3 2025 at Standard Biotools, down from $108000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $213.0 million in Q2 2022 to a low of -$54.5 million in Q4 2024.
  • A 5-year average of $7.2 million and a median of -$133000.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 160218.8% in 2022, then plummeted 23180.0% in 2023.
  • Standard Biotools' Cash from Financing Activities stood at $7.3 million in 2021, then tumbled by 103.7% to -$270000.0 in 2022, then plummeted by 271.48% to -$1.0 million in 2023, then tumbled by 5335.69% to -$54.5 million in 2024, then skyrocketed by 99.79% to -$112000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash from Financing Activities are -$112000.0 (Q3 2025), $108000.0 (Q2 2025), and -$46000.0 (Q1 2025).